|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
gptkb:Immunomedics
Kite Pharma
Pharmacyclics
|
|
gptkbp:CEO
|
gptkb:Daniel_O'Day
|
|
gptkbp:clinicalTrials
|
HIV vaccine trials
oncology trials
COVID-19 treatment trials
Hepatitis C trials
|
|
gptkbp:employees
|
10,000+ (2021)
|
|
gptkbp:focus
|
oncology
inflammation
Hepatitis C treatment
cell therapy
HIV/AIDS treatment
|
|
gptkbp:founded
|
1987
|
|
gptkbp:founder
|
gptkb:Michael_L._Riordan
|
|
gptkbp:headquarters
|
gptkb:Foster_City,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
GILD
|
|
gptkbp:market
|
$80 billion (2021)
|
|
gptkbp:netIncome
|
$5.6 billion (2020)
|
|
gptkbp:partnerships
|
Gilead_Sciences_and_Bristol-Myers_Squibb
Gilead_Sciences_and_Galapagos_NV
Gilead_Sciences_and_Kite_Pharma
Gilead_Sciences_and_Merck
|
|
gptkbp:philanthropy
|
gptkb:Gilead_Foundation
Gilead's_COVID-19_response
Gilead's_HIV/AIDS_programs
|
|
gptkbp:products
|
gptkb:Yescarta
gptkb:Sovaldi
Biktarvy
Harvoni
Zydelig
Genvoya
|
|
gptkbp:revenue
|
$27.1 billion (2020)
|
|
gptkbp:stockSymbol
|
gptkb:GILD
|
|
gptkbp:subsidiary
|
gptkb:Gilead_Sciences_UK_Ltd.
gptkb:Gilead_Sciences_Singapore_Pte._Ltd.
gptkb:Gilead_Sciences_Japan,_Inc.
gptkb:Gilead_Sciences_France_S.A.S.
gptkb:Gilead_Sciences_Germany_GmbH
gptkb:Gilead_Sciences_Ireland_UC
gptkb:Gilead_Sciences_Canada,_Inc.
gptkb:Gilead_Sciences_Australia_Pty_Ltd.
gptkb:Gilead_Sciences_Switzerland_AG
gptkb:Gilead_Sciences_Netherlands_B.V.
|
|
gptkbp:sustainability
|
Gilead's_community_engagement_programs
Gilead's_diversity_and_inclusion_efforts
Gilead's_environmental_initiatives
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|